Liminal Biosciences Inc. (LMNL): Price and Financial Metrics
LMNL Price/Volume Stats
| Current price | $8.50 | 52-week high | $8.50 |
| Prev. close | $8.49 | 52-week low | $3.10 |
| Day low | $8.48 | Volume | 5,000 |
| Day high | $8.50 | Avg. volume | 63,470 |
| 50-day MA | $8.40 | Dividend yield | N/A |
| 200-day MA | $6.23 | Market Cap | 26.38M |
LMNL Stock Price Chart Interactive Chart >
Liminal Biosciences Inc. (LMNL) Company Bio
Liminal Biosciences Inc. operates as a bio-pharmaceutical company. The Company, through its subsidiaries, researches, develops, manufactures, and markets a variety of commercial applications from its core technology. Liminal's applications are used in therapeutics, large-scale drug purification, chemical genomics and proteomics, and drug development.
Latest LMNL News From Around the Web
Below are the latest news stories about LIMINAL BIOSCIENCES INC that investors may wish to consider to help them evaluate LMNL as an investment opportunity.
LIMINAL BIOSCIENCES RECEIVES FINAL COURT ORDER FOR PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LPLiminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), is pleased to announce that it received the final order of the Ontario Superior Court of Justice (Commercial List) approving the previously-announced plan of arrangement under section 192 of the Canada Business Corporations Act (the "Arrangement") pursuant to which Structured Alpha LP ("SALP"), a limited partnership managed by its general partner, Thomvest Asset Management Ltd., will acquire all of the issued and o |
LIMINAL BIOSCIENCES SHAREHOLDERS APPROVE PLAN OF ARRANGEMENT WITH STRUCTURED ALPHA LPLiminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), is pleased to announce that its shareholders have approved the previously-announced plan of arrangement under section 192 of the Canada Business Corporations Act (the "Arrangement") pursuant to which Structured Alpha LP ("SALP"), a limited partnership managed by its general partner, Thomvest Asset Management Ltd., will acquire all of the issued and outstanding common shares of Liminal BioSciences (the "Shares") not |
LIMINAL BIOSCIENCES FILES AMENDED SCHEDULE 13E-3 AND SUPPLEMENT TO THE MANAGEMENT INFORMATION CIRCULARLiminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), announced that an amendment to the previously filed Schedule 13E-3 will be filed to address comments raised by the Securities and Exchange Commission ("SEC") in connection with the previously announced plan of arrangement involving the acquisition by Structured Alpha LP ("SALP"), a limited partnership managed by its general partner, Thomvest Asset Management Ltd., of all of the issued and outstanding common shares |
LIMINAL BIOSCIENCES OBTAINS INTERIM ORDER FOR PROPOSED ARRANGEMENT WITH STRUCTURED ALPHA LPLiminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), announced today that the Ontario Superior Court of Justice (Commercial List) (the "Court") has issued an interim order (the "Interim Order") in connection with the previously-announced plan of arrangement under section 192 of the Canada Business Corporations Act (the "Plan of Arrangement") pursuant to which Structured Alpha LP ("SALP"), a limited partnership managed by its general partner, Thomvest Asset Management |
Liminal BioSciences Reports Second Quarter Financial Results 2023Liminal BioSciences Inc. (Nasdaq: LMNL) ("Liminal BioSciences" or the "Company"), a development-stage biopharmaceutical company focused on discovering and developing distinctive novel small molecule therapeutics for metabolic, inflammatory, and fibrotic diseases, today reported its financial results for the second quarter ended June 30, 2023. |
LMNL Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | 27.25% |
| 3-year | -81.84% |
| 5-year | -98.30% |
| YTD | N/A |
| 2023 | 0.00% |
| 2022 | -70.18% |
| 2021 | -74.05% |
| 2020 | -49.88% |
| 2019 | -95.69% |
Loading social stream, please wait...